ASIC heads into late July having gained 9.3% on the week and nearly 11% over the past month, with the Street's upgrading pencils doing most of the heavy lifting.
The analyst story is unusually clean. Every major firm covering the stock has raised its price target in recent weeks, and all maintain Overweight ratings — a rare unanimous bullish chorus in specialty insurance. JP Morgan lifted its target to $29 on July 20, Wells Fargo moved to $30 on July 9, and Barclays raised to $28 on July 7. Those moves followed years of incrementally rising targets from the same names, forming a steady upward staircase. The consensus mean sits at $28.20 against a close of $25.59, implying roughly 10% additional upside from here. The sole dissenter remains Citi, which downgraded to Neutral back in February — an outlier in an otherwise solidly bullish coverage universe. Factor scores support the thesis: EPS surprise ranks in the 80th percentile, 90-day EPS momentum in the 83rd, and dividend score at 79. The P/E of roughly 11x and price-to-book near 1.6x remain undemanding for a specialty insurer growing into firmer underwriting conditions.
Short interest is a non-story at this price level. Bears have been pulling back steadily — the short position has fallen 24% over the past week and 15% over the past month to just 0.47% of the free float. The borrow market is deeply relaxed, with shares-to-borrow running at nearly 19 times the current short position, well above normal. Cost to borrow is a negligible 0.70%, even after creeping up roughly 18% on the week. There is no squeeze dynamic here, no crowded short position unwinding — shorts are simply absent.
The ownership picture carries one notable feature. Zimmer Financial Services holds 80% of shares outstanding, making this a tightly controlled float. T. Rowe Price added nearly 80,000 shares in Q2, and BlackRock added 119,000 in the same period, both active additions rather than passive drift. That institutional buying into a thin float helps explain the stock's clean upward trend. On the insider side, the CEO purchased shares at roughly $19.40 last October, and the President added a small tranche in May at $19.99 — both well below the current price of $25.59, giving those insiders a solid unrealised cushion.
Earnings are the next variable. ASIC reported what appears to be a Q2 event on July 29, with the announcement made just days prior on July 23. The only historical reaction data available is a June 9 print that produced a one-day gain of 4.9% and a five-day gain of 6.0% — a strongly positive market response to results. Whether today's print generates a similar response, or whether the stock's recent run has already priced in the good news, is the setup worth watching as post-earnings positioning becomes clearer.
See the live data behind this article on ORTEX.
Open ASIC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
